Concord Biotech
Ticker > Company >

Concord Biotech share price

Concord Biotech Ltd.

NSE: CONCORDBIO BSE: 543960 SECTOR: Pharmaceuticals & Drugs  51k   80   11

2129.35
+4.15 (0.20%)
NSE: 20 Dec 04:02 PM

Price Summary

Today's High

₹ 2162.95

Today's Low

₹ 2096.05

52 Week High

₹ 2664

52 Week Low

₹ 1327.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 22276.45 Cr.

Enterprise Value

₹ 22235.66 Cr.

No. of Shares

10.46 Cr.

P/E

67.77

P/B

14.01

Face Value

₹ 1

Div. Yield

0.41 %

Book Value (TTM)

₹  152.04

CASH

₹ 47.02 Cr.

DEBT

₹ 6.23 Cr.

Promoter Holding

44.08 %

EPS (TTM)

₹  31.42

Sales Growth

19.2%

ROE

21.63 %

ROCE

28.89%

Profit Growth

27.97 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year19.2%
3 Year18.13%
5 Year18.46%

Profit Growth

1 Year27.97%
3 Year9%
5 Year20.82%

ROE%

1 Year21.63%
3 Year19.48%
5 Year21.66%

ROCE %

1 Year28.89%
3 Year25.77%
5 Year27.75%

Debt/Equity

0.0041

Price to Cash Flow

83.91

Interest Cover Ratio

129.5156

CFO/PAT (5 Yr. Avg.)

0.924347913219257

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 44.08 0.00
Jun 2024 44.08 0.00
Mar 2024 44.08 0.00
Dec 2023 44.08 0.00
Sep 2023 44.08 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 18.12701019075% for the Past 3 years.
  • The company has significantly decreased its debt by 25.0058 Cr.
  • Company has been maintaining healthy ROCE of 25.7733727690157% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 129.5156.
  • The Company has been maintaining an effective average operating margins of 42.9710206050781% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 37.4076 days.
  • Company has a healthy liquidity position with current ratio of 6.3046.

 Limitations

  • The company has shown a poor profit growth of 8.99600717892104% for the Past 3 years.
  • The company is trading at a high PE of 67.77.
  • The company is trading at a high EV/EBITDA of 44.8937.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 262.35 240.8 318.97 215.8 310.18
Total Expenditure 143.16 134.87 184.68 134.52 173.5
Operating Profit 119.19 105.93 134.29 81.28 136.68
Other Income 8.13 8.19 10.81 10.31 10.03
Interest 0.84 0.5 0.46 0.24 0.1
Depreciation 13.3 13.54 13.72 13.18 13.31
Exceptional Items 0 0 0 0 0
Profit Before Tax 113.18 100.09 130.92 78.17 133.29
Tax 28.69 25.53 33.7 19.93 34.59
Profit After Tax 84.49 74.55 97.22 58.24 98.7
Adjusted EPS (Rs) 8.08 7.13 9.29 5.57 9.43

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 512.33 616.94 712.93 853.17 1016.94
Total Expenditure 307.79 289.01 439.01 504.59 584.75
Operating Profit 204.54 327.93 273.93 348.58 432.19
Other Income 31.37 13.81 23.42 35.31 33.78
Interest 1.17 1.05 6.13 9.8 3.18
Depreciation 21.25 27.52 50.05 54.03 53.59
Exceptional Items 0 0 0 0 0
Profit Before Tax 213.49 313.17 241.16 320.05 409.19
Tax 44.53 77.83 62.59 81.93 104.46
Net Profit 168.96 235.29 178.57 238.13 304.73
Adjusted EPS (Rs.) 16.15 22.5 17.07 22.76 29.13

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 9.51 9.51 9.51 10.46 10.46
Total Reserves 760.57 990.16 1097.65 1281.52 1514.79
Borrowings 35.53 56.25 31.25 6.24 0
Other N/C liabilities 19.66 151.37 212.23 25.9 31.91
Current liabilities 223.27 105.74 151.89 190.53 142.16
Total Liabilities 1048.54 1313.03 1502.53 1514.65 1699.32
Assets
Net Block 239.6 546.22 572.98 592.98 575.32
Capital WIP 141.4 17.95 74.16 172.7 211.48
Intangible WIP 0 0 0 0 0
Investments 0.67 0.67 0.92 0.79 0.67
Loans & Advances 19.44 140.61 220.99 11.61 12.81
Other N/C Assets 0.67 0.45 0.82 8.87 2.81
Current Assets 646.76 607.15 632.67 727.7 896.23
Total Assets 1048.54 1313.03 1502.53 1514.65 1699.32
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 213.49 313.17 241.16 320.05 409.19
Adjustment 12.27 17.59 49.16 48.51 40.8
Changes in Assets & Liabilities -21.85 -88.77 -22.06 -52.29 -81.18
Tax Paid -49.1 -75.18 -60.78 -70.28 -103.35
Operating Cash Flow 154.81 166.81 207.47 246 265.47
Investing Cash Flow -112.74 -195.2 -111.79 -157.95 -154.61
Financing Cash Flow -43.41 31.12 -100.16 -85.22 -99.21
Net Cash Flow -1.35 2.74 -4.48 2.83 11.64

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 44.08 44.08 44.08 44.08 44.08
ankur sudhir vaid 0.56 0.56 0.56 0.56 0.56
manju vaid 9.55 9.55 9.55 9.55 9.55
sonal kumra 0.07 0.07 0.07 0.07 0.07
sudhir vaid 28.84 28.84 28.84 28.84 28.84
sudman consultants llp 4.54 4.54 4.54 4.54 4.54
vaid megha ankur 0.52 0.52 0.52 0.52 0.52
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 55.92 55.92 55.92 55.92 55.92
amal n parikh 1.93 1.93 1.93 1.93 1.93
aryaman jhunjhunwala disc... 8.03 8.03 8.03 8.03 8.03
aryavir jhunjhunwala disc... 8.03 8.03 8.03 8.03 8.03
chanakya corporate servic... 1.11 1.11 1.11 1.11 1.11
government pension fund g... 1.82 1.99 2.16 2.68 2.56
hsbc small cap fund - - - - 1.02
invesco india flexi cap f... - - - - 1.04
max life insurance compan... - - - - 1.91
nishtha jhunjhunwala disc... 8.03 8.03 8.03 8.03 8.03
ravindra raichand dharams... 1.93 1.93 1.93 1.93 1.54
tata aia life insurance c... - - - 1.93 1.89
1575773 ontario inc 5.39 5.39 5.39 2.00 -
invesco india flex cap fu... - - - 1.08 -
llp 0.11 0.12 0.12 0.15 -
max life insurance compan... - - - 1.98 -
max life insurance co lt... 1.20 1.62 1.52 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Company News

Concord Biotech informs about acquisition 12 Dec, 1:55 PM Concord Biotech informs about earnings call transcript 19 Nov, 12:26 PM Concord Biotech - Quaterly Results 11 Nov, 1:08 PM Concord Biotech - Quaterly Results 11 Nov, 1:08 PM Concord Biotech - Quaterly Results 11 Nov, 1:08 PM Concord Biotech informs about board meeting 6 Nov, 11:01 AM Concord Biotech informs about earnings call 6 Nov, 10:57 AM Concord Biotech informs about closure of trading window 25 Sep, 4:56 PM Concord Biotech informs about clarification on price movement 24 Sep, 2:58 PM Concord Biotec informs about investor meeting 30 Aug, 12:09 PM Concord Biotech - Quaterly Results 9 Aug, 1:41 PM Concord Biotech - Quaterly Results 9 Aug, 1:41 PM Concord Biotech - Quaterly Results 9 Aug, 1:41 PM Concord Biotech informs about voting results and scrutinizer report 2 Jul, 11:10 AM Concord Biotech informs about annual report 1 Jul, 2:41 PM Health Product Regulatory Authority issues EUGMP certificate to Concord Biotech’s Valthera facility 6 Jun, 12:27 PM Concord Biotech informs about earnings call transcript 4 Jun, 5:11 PM Concord Biotech informs about disclosures 29 May, 4:20 PM Concord Biotech - Quaterly Results 23 May, 3:36 PM Concord Biotech - Quaterly Results 23 May, 3:36 PM Concord Biotech - Quaterly Results 23 May, 3:36 PM Concord Biotech informs about earning call 21 May, 11:08 AM Saudi Food and Drug Authority completes inspection at Concord Biotech’s manufacturing unit II 17 May, 4:12 PM Concord Biotech informs about updates 6 Mar, 5:22 PM Concord Biotech gets GMP for unit II of Gujarat facility 23 Feb, 11:46 AM Concord Biotech informs about investor presentation 9 Feb, 1:20 PM Concord Biotech - Quaterly Results 8 Feb, 6:15 PM Concord Biotech - Quaterly Results 8 Feb, 6:15 PM Concord Biotech informs about board meeting 30 Jan, 4:12 PM Concord Biotech informs about analyst meet 14 Dec, 5:24 PM Concord Biotech - Quaterly Results 8 Nov, 3:19 PM Concord Biotech - Quaterly Results 8 Nov, 3:19 PM Concord Biotech informs about updates 11 Oct, 4:21 PM Concord Biotech informs about conference call 13 Sep, 5:17 PM Concord Biotech - Quaterly Results 6 Sep, 3:44 PM Concord Biotech - Quaterly Results 6 Sep, 3:44 PM Concord Biotech - Quaterly Results 6 Sep, 3:44 PM Concord Biotech gets EIR from USFDA for Gujarat facility 18 Aug, 4:00 PM Concord Biotech coming up with IPO to raise upto Rs 1551 crore 2 Aug, 3:05 PM Concord Biotech to come out with Rs 1,550 crore IPO on August 4 31 Jul, 12:47 PM

Concord Biotech Stock Price Analysis and Quick Research Report. Is Concord Biotech an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Concord Biotech and its performance over the period of time. Concord Biotech stock price today is Rs 2129.35.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Concord Biotech cash from the operating activity was Rs 265.4671 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Concord Biotech has a Debt to Equity ratio of 0.0041 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Concord Biotech , the EPS growth was 27.9709 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Concord Biotech has OPM of 42.4990205904148 % which is a good sign for profitability.
     
  • ROE: Concord Biotech have a healthy ROE of 21.6334 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Concord Biotech is Rs 2129.35. One can use valuation calculators of ticker to know if Concord Biotech share price is undervalued or overvalued.
Last Updated on:
Brief about Concord Biotech

Concord Biotech Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Concord Biotech Ltd. is a renowned biotechnology company that specializes in the development and manufacturing of fermentation-based products. With a strong focus on research and development, the company has established itself as a leader in the biopharmaceutical and nutraceutical industries. Founded in the year XXXX, Concord Biotech has consistently delivered innovative solutions to its customers.

Concord Biotech Ltd. Stock Analysis – Share Price

The share price of Concord Biotech Ltd. reflects the market's perception of the company's future prospects. As a long-term stock investor, understanding the factors that influence the share price is crucial. At our website, you can monitor and analyze the historical share price movements of Concord Biotech Ltd. using our pre-built screening tools.

Concord Biotech Ltd. Stock Analysis – Balance Sheet

The balance sheet of Concord Biotech Ltd. provides insights into the company's financial position and its ability to meet its obligations. As a long-term investor, analyzing the balance sheet is essential to understand the company's assets, liabilities, and equity. At our website, you can access the company's annual reports for a comprehensive review of its balance sheet. Our premium features, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, enable fair value calculation for informed investment decisions.

Concord Biotech Ltd. Stock Analysis – Annual Report

The annual report of Concord Biotech Ltd. provides comprehensive information about the company's financial performance, business strategies, and future outlook. At our website, you can download the annual reports of Concord Biotech Ltd. for a detailed analysis and better understanding of the company's operations.

Concord Biotech Ltd. Stock Analysis – Dividend

Dividends are an important consideration for long-term investors as they provide a regular income stream. Concord Biotech Ltd. has a consistent track record of rewarding its shareholders through dividends. By analyzing the company's dividend history, investors can assess its financial stability and the potential for future dividend payouts.

Concord Biotech Ltd. Stock Analysis – Quarterly Result

Analyzing the quarterly results of Concord Biotech Ltd. allows investors to gauge the company's financial performance on a regular basis. Our website provides access to the quarterly reports of Concord Biotech Ltd., enabling investors to stay updated with the latest financial results and make informed investment decisions.

Concord Biotech Ltd. Stock Analysis – Stock Price

The stock price of Concord Biotech Ltd. is influenced by various factors, including market sentiment, industry trends, and the company's financial performance. By monitoring the stock price movements and trends, investors can identify potential buying or selling opportunities. Our website provides a price chart for Concord Biotech Ltd., allowing investors to visualize the historical stock price data.

Concord Biotech Ltd. Stock Analysis – Price Chart

Our website offers a price chart feature that allows investors to analyze the historical stock price movements of Concord Biotech Ltd. This tool enables users to identify trends, patterns, and potential price levels for informed decision-making.

Concord Biotech Ltd. Stock Analysis – News

Keeping track of the latest news and developments related to Concord Biotech Ltd. is essential for investors. Our website provides a dedicated news section where users can access the latest news articles and updates about the company. Staying informed about industry trends, regulatory changes, and company-specific news is crucial for effective stock analysis.

Concord Biotech Ltd. Stock Analysis – Concall and Transcripts

Concalls (conference calls) are an important source of information for investors as they provide insights into a company's performance, strategies, and future outlook. At our website, you can access the concall transcripts of Concord Biotech Ltd., allowing you to stay updated with the management's discussions and analysis of the company's operations.

Concord Biotech Ltd. Stock Analysis – Investor Presentations

Investor presentations play a significant role in understanding a company's business model, growth plans, and strategic initiatives. Concord Biotech Ltd. provides investor presentations that offer valuable insights into the company's operations and opportunities. By analyzing these presentations, investors can gain a deeper understanding of Concord Biotech Ltd.'s growth prospects and investment potential.

Concord Biotech Ltd. Stock Analysis – Promoters and Shareholders

The promoters and major shareholders of Concord Biotech Ltd. play a crucial role in shaping the company's direction and decision-making. Understanding the key stakeholders can provide insights into their commitment to the company's success. At our website, you can access information about the promoters and major shareholders of Concord Biotech Ltd., helping you evaluate their influence on the company's operations and future plans.

In conclusion, Concord Biotech Ltd. presents an attractive opportunity for long-term stock investors seeking to analyze the company's performance and prospects. Our website offers various tools and resources, including pre-built screening tools, annual reports, concall transcripts, investor presentations, and premium features like fair value calculation using DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis. Stay informed and make informed investment decisions with our comprehensive stock analysis tools and information on Concord Biotech Ltd.

Read More
X